Royalty Pharma PLCNASDAQ:RPRX
- LAST PRICE26.4100
- TODAY'S CHANGE (%)0.0100 (0.0379%)
- Bid / Lots26.4000/ 8
- Ask / Lots26.4100/ 7
- Open / Previous Close26.3800 / 26.4000
- Day Range
- 52 Week Range
- Volume1,060,266
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPRX |
|---|---|---|
| 09:32 ET | 33500 | 26.43 |
| 09:33 ET | 7009 | 26.385 |
| 09:35 ET | 19070 | 26.465 |
| 09:37 ET | 21180 | 26.545 |
| 09:39 ET | 6517 | 26.575 |
| 09:42 ET | 35579 | 26.585 |
| 09:44 ET | 2708 | 26.57 |
| 09:46 ET | 34970 | 26.62 |
| 09:48 ET | 5207 | 26.62 |
| 09:50 ET | 1292 | 26.59 |
| 09:51 ET | 3106 | 26.59 |
| 09:53 ET | 3778 | 26.55 |
| 09:55 ET | 3232 | 26.53 |
| 09:57 ET | 2758 | 26.535 |
| 10:00 ET | 2732 | 26.56 |
| 10:02 ET | 3278 | 26.475 |
| 10:04 ET | 2428 | 26.46 |
| 10:06 ET | 5280 | 26.44 |
| 10:08 ET | 5678 | 26.45 |
| 10:09 ET | 4735 | 26.43 |
| 10:11 ET | 6611 | 26.41 |
| 10:13 ET | 14833 | 26.425 |
| 10:15 ET | 3679 | 26.435 |
| 10:18 ET | 8750 | 26.44 |
| 10:20 ET | 21799 | 26.495 |
| 10:22 ET | 3044 | 26.505 |
| 10:24 ET | 3073 | 26.5 |
| 10:26 ET | 6876 | 26.49 |
| 10:27 ET | 4048 | 26.45 |
| 10:29 ET | 2440 | 26.432665 |
| 10:31 ET | 6578 | 26.43 |
| 10:33 ET | 6600 | 26.45 |
| 10:36 ET | 6848 | 26.435 |
| 10:38 ET | 6024 | 26.44 |
| 10:40 ET | 20108 | 26.465 |
| 10:42 ET | 2644 | 26.45 |
| 10:44 ET | 3468 | 26.43 |
| 10:45 ET | 1129 | 26.43 |
| 10:47 ET | 3994 | 26.44 |
| 10:49 ET | 13622 | 26.44 |
| 10:51 ET | 13158 | 26.46 |
| 10:54 ET | 7063 | 26.46 |
| 10:56 ET | 600 | 26.46 |
| 10:58 ET | 12404 | 26.4875 |
| 11:00 ET | 3907 | 26.485 |
| 11:02 ET | 8387 | 26.47 |
| 11:03 ET | 2872 | 26.46 |
| 11:05 ET | 10769 | 26.47 |
| 11:07 ET | 2494 | 26.445 |
| 11:09 ET | 1416 | 26.445 |
| 11:12 ET | 6686 | 26.445 |
| 11:14 ET | 2267 | 26.453 |
| 11:16 ET | 5317 | 26.465 |
| 11:18 ET | 2328 | 26.455 |
| 11:20 ET | 2133 | 26.445 |
| 11:21 ET | 5825 | 26.4207 |
| 11:23 ET | 8019 | 26.44 |
| 11:25 ET | 7144 | 26.4 |
| 11:27 ET | 15950 | 26.35 |
| 11:30 ET | 5872 | 26.345 |
| 11:32 ET | 2401 | 26.35 |
| 11:34 ET | 7511 | 26.34 |
| 11:36 ET | 4946 | 26.34 |
| 11:38 ET | 2589 | 26.355 |
| 11:39 ET | 6113 | 26.37 |
| 11:41 ET | 11774 | 26.36 |
| 11:43 ET | 5757 | 26.35 |
| 11:45 ET | 3722 | 26.38 |
| 11:48 ET | 5815 | 26.39 |
| 11:50 ET | 7270 | 26.415 |
| 11:52 ET | 11453 | 26.395 |
| 11:54 ET | 2782 | 26.39 |
| 11:56 ET | 4564 | 26.42 |
| 11:57 ET | 9981 | 26.425 |
| 11:59 ET | 4969 | 26.435 |
| 12:01 ET | 23402 | 26.4237 |
| 12:03 ET | 8295 | 26.43 |
| 12:06 ET | 11450 | 26.435 |
| 12:08 ET | 31297 | 26.38 |
| 12:10 ET | 4306 | 26.38 |
| 12:12 ET | 3674 | 26.375 |
| 12:14 ET | 2534 | 26.37 |
| 12:15 ET | 2052 | 26.37 |
| 12:17 ET | 35191 | 26.415 |
| 12:19 ET | 9183 | 26.405 |
| 12:21 ET | 6105 | 26.42 |
| 12:24 ET | 9337 | 26.445 |
| 12:26 ET | 13858 | 26.455 |
| 12:28 ET | 4382 | 26.445 |
| 12:30 ET | 2670 | 26.435 |
| 12:32 ET | 8055 | 26.42 |
| 12:33 ET | 525 | 26.415 |
| 12:35 ET | 4527 | 26.415 |
| 12:37 ET | 1666 | 26.415 |
| 12:39 ET | 981 | 26.42 |
| 12:42 ET | 10278 | 26.44 |
| 12:44 ET | 5032 | 26.43 |
| 12:46 ET | 2631 | 26.44 |
| 12:48 ET | 9122 | 26.455 |
| 12:50 ET | 3196 | 26.465 |
| 12:51 ET | 9443 | 26.455 |
| 12:53 ET | 3118 | 26.455 |
| 12:55 ET | 6679 | 26.425 |
| 12:57 ET | 5079 | 26.42 |
| 01:00 ET | 1104 | 26.43 |
| 01:02 ET | 4933 | 26.44 |
| 01:04 ET | 1400 | 26.43 |
| 01:06 ET | 1200 | 26.425 |
| 01:08 ET | 2301 | 26.415 |
| 01:09 ET | 3000 | 26.415 |
| 01:11 ET | 1100 | 26.425 |
| 01:13 ET | 1397 | 26.43 |
| 01:15 ET | 2928 | 26.43 |
| 01:18 ET | 2300 | 26.44 |
| 01:20 ET | 1570 | 26.4346 |
| 01:22 ET | 4493 | 26.4306 |
| 01:24 ET | 4545 | 26.44 |
| 01:26 ET | 1424 | 26.435 |
| 01:27 ET | 2544 | 26.44 |
| 01:29 ET | 4676 | 26.435 |
| 01:31 ET | 3005 | 26.44 |
| 01:33 ET | 2539 | 26.4305 |
| 01:36 ET | 530 | 26.43 |
| 01:38 ET | 2805 | 26.435 |
| 01:40 ET | 3239 | 26.42 |
| 01:42 ET | 5452 | 26.3975 |
| 01:44 ET | 800 | 26.395 |
| 01:45 ET | 1541 | 26.395 |
| 01:47 ET | 807 | 26.41 |
Nov 14, 2024
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million, from 7:10AM ET on Thursday Nov 07, 2024 by Dow Jones
7:10AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Royalty Pharma Reports Third Quarter 2024 Results, from 7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones*DJ Royalty Pharma 3Q Net $544M >RPRX, from 7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 4, 2024
Press Release: Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo, from 4:15PM ET on Monday Nov 04, 2024 by Dow Jones
4:15PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Royalty Pharma PLC | 15.6B | 10.3x | +1.83% |
Amneal Pharmaceuticals Inc | 2.6B | -12.1x | --- |
Catalent Inc | 10.8B | -26.9x | --- |
Endo Inc | 1.9B | 0.4x | --- |
Jazz Pharmaceuticals PLC | 7.6B | 17.9x | -3.53% |
Prestige Consumer Healthcare Inc | 4.2B | 20.6x | --- |
Company Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Contact Information
- Headquarters
- 110 East 59th StreetNEW YORK, NY, United States 10022
- Phone
- 212-883-0200
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Pablo Legorreta
- Vice Chairman, Executive Vice President
- Christopher Hite
- Chief Financial Officer, Executive Vice President
- Terrance Coyne
- Executive Vice President - Investments and Chief Legal Officer
- George Lloyd
- Executive Vice President - Head of Human Capital
- Molly Sawaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.6B |
|---|---|
Revenue (TTM) | $2.3B |
Shares Outstanding | 589.2M |
Dividend Yield | 3.18% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 11-15-24 |
Pay Date | 12-10-24 |
Beta | 0.46 |
EPS | $2.56 |
Book Value | $14.61 |
P/E Ratio | 10.3x |
Price/Sales (TTM) | 6.9 |
Price/Cash Flow (TTM) | 21.7x |
Operating Margin | 68.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
